Vertex Pharmaceuticals Inc (VRTX)
408.76
-1.89
(-0.46%)
USD |
NASDAQ |
Dec 27, 16:00
408.98
+0.22
(+0.05%)
After-Hours: 20:00
Vertex Pharmaceuticals SG&A Expense (Quarterly): 371.80M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 2.100B |
| Gilead Sciences Inc | 1.433B |
| Pfizer Inc | 3.244B |
| Bristol-Myers Squibb Co | 1.983B |
| PTC Therapeutics Inc | 73.46M |